Teslexivir - Aviragen Therapeutics

Drug Profile

Teslexivir - Aviragen Therapeutics

Alternative Names: AP 611; AP611074; BTA-074

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anaconda Pharma
  • Developer Anaconda Pharma; Aviragen Therapeutics
  • Class Antivirals; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Condylomata acuminata
  • Clinical Phase Unknown Recurrent respiratory papillomatosis

Most Recent Events

  • 20 Nov 2017 Chemical structure information added
  • 02 Nov 2017 BTA 074 is now called teslexivir
  • 12 Apr 2016 Biota Pharmaceuticals is now called Aviragen Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top